In these difficult times, we’ve made a number of our coronavirus articles free for all readers. To get all of HBR’s content delivered to your inbox, sign up for the Daily Alert newsletter.

Vaccine experts around the world are justifiably concerned by the lack of scientific data on the “Sputnik V” vaccine for Covid-19 that Russia recently approved after less than two months of human testing on a non-randomized group of 39 patients. But they are also worried about the potentially chilling effect its possible failure could have on public acceptance of whichever of the dozens of other Covid-19 vaccines in the pipeline eventually proves safe and effective. Business leaders should be concerned as well and must begin to play a central role now in building public confidence in vaccines.